Pfizer Inc. $PFE Shares Purchased by Pallas Capital Advisors LLC

Pallas Capital Advisors LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 98.7% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 61,797 shares of the biopharmaceutical company’s stock after purchasing an additional 30,691 shares during the period. Pallas Capital Advisors LLC’s holdings in Pfizer were worth $1,575,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its position in shares of Pfizer by 1.9% during the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares during the period. Geode Capital Management LLC lifted its stake in Pfizer by 1.4% during the 2nd quarter. Geode Capital Management LLC now owns 127,471,481 shares of the biopharmaceutical company’s stock worth $3,080,552,000 after acquiring an additional 1,820,634 shares in the last quarter. Norges Bank purchased a new position in Pfizer during the 2nd quarter valued at about $2,270,157,000. Charles Schwab Investment Management Inc. boosted its holdings in Pfizer by 2.4% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 49,165,032 shares of the biopharmaceutical company’s stock valued at $1,191,760,000 after acquiring an additional 1,135,457 shares during the period. Finally, Fisher Asset Management LLC grew its position in Pfizer by 2.0% in the 2nd quarter. Fisher Asset Management LLC now owns 48,390,268 shares of the biopharmaceutical company’s stock valued at $1,172,980,000 after acquiring an additional 950,239 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $27.58 on Tuesday. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97. The firm has a market capitalization of $156.78 billion, a PE ratio of 20.28 and a beta of 0.47. The business’s fifty day moving average price is $25.84 and its 200 day moving average price is $25.23.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.25% and a net margin of 12.42%.The business had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the firm posted $0.63 EPS. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 6.2%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio is currently 126.47%.

Wall Street Analyst Weigh In

PFE has been the topic of several research reports. Zacks Research cut shares of Pfizer from a “hold” rating to a “strong sell” rating in a research report on Monday, January 26th. Citigroup began coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price on the stock. Bank of America decreased their price target on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating for the company in a research report on Monday, December 15th. BMO Capital Markets reaffirmed an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. Finally, Guggenheim reissued a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $28.00.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.